Skip to search formSkip to main contentSkip to account menu

mogamulizumab

Known as: Immunoglobulin G1, Anti-(CC Chemokine Receptor CCR4) (Human-Mouse Monoclonal KW-0761 Heavy Chain), Disulfide With Human-Mouse Monoclonal KW-0761 Kappa-Chain, Dimer 
A humanized monoclonal antibody directed against C-C chemokine receptor 4 (CCR4) with potential anti-inflammatory and antineoplastic activities… 
National Institutes of Health

Related topics

Related topics

7 relations

Narrower (2)

AMG 761KW 0761

Broader (1)

Antibodies, Monoclonal, Humanized
Antibody-Dependent Cellular CytotoxicityNCIt Antineoplastic Agent TerminologyT-Lymphocyteantigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2018
Highly Cited
2018
CCR4 mutations associated with superior outcome of adult T-cell leukemia/lymphoma under mogamulizumab treatment.
TO THE EDITOR: Adult T-cell leukemia/lymphoma (ATL) is caused by human T-cell lymphotropic virus type 1.[1][1][⇓][2]-[3][3… 
Review
2018
Review
2018
Antibodies to watch in 2019
ABSTRACT For the past 10 years, the annual ‘Antibodies to watch’ articles have provided updates on key events in the late-stage… 
Highly Cited
2018
Highly Cited
2018
Mogamulizumab (Anti‐CCR4) in HTLV‐1–Associated Myelopathy
BACKGROUND Human T‐lymphotropic virus type 1 (HTLV‐1) causes the debilitating neuroinflammatory disease HTLV‐1–associated… 
Review
2018
Review
2018
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or…
Highly Cited
2016
Highly Cited
2016
Pretransplantation Anti-CCR4 Antibody Mogamulizumab Against Adult T-Cell Leukemia/Lymphoma Is Associated With Significantly Increased Risks of Severe and Corticosteroid-Refractory Graft-Versus-Host…
PURPOSE Allogeneic hematopoietic stem-cell transplantation (allo-HSCT) is one important treatment option for patients with… 
Highly Cited
2015
Highly Cited
2015
Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma.
This phase 1/2 study evaluated the efficacy of mogamulizumab, a defucosylated, humanized, anti-CC chemokine receptor 4 monoclonal… 
Highly Cited
2015
Highly Cited
2015
Dose‐intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T‐cell leukaemia‐lymphoma: a randomized phase II study
This multicentre, randomized, phase II study was conducted to examine whether the addition of mogamulizumab, a humanized anti‐CC… 
Highly Cited
2013
Highly Cited
2013
Stevens–Johnson Syndrome associated with mogamulizumab treatment of adult T‐cell leukemia / lymphoma
We report an adult T‐cell leukemia/lymphoma patient suffering from Stevens–Johnson Syndrome (SJS) during mogamulizumab (humanized… 
Highly Cited
2012
Highly Cited
2012
Mogamulizumab
Mogamulizumab (Poteligeo®) is a defucosylated, humanized monoclonal antibody targeting CC chemokine receptor 4 (CCR4… 
Highly Cited
2010
Highly Cited
2010
Defucosylated Humanized Anti-CCR4 Monoclonal Antibody KW-0761 as a Novel Immunotherapeutic Agent for Adult T-cell Leukemia/Lymphoma
Purpose: Adult T-cell leukemia/lymphoma (ATLL) has a very poor prognosis. We have developed the humanized defucosylated anti–CC… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)